

Annual General Meeting of BioNTech SE

15 May 2026

Please note: This is a convenience translation. The German version as given in the simultaneous translation shall prevail.

Ramón Zapata, Chief Financial Officer

Dear shareholders, shareholder representatives, ladies and gentlemen,

A very warm welcome from me as well to our Annual General Meeting today. I am delighted to be here for my first AGM as BioNTech's Chief Financial Officer having joined the company in mid-2025. I will also be speaking in English rather than German for this presentation.

Looking back on the 2025 fiscal year, we can report significant progress toward realizing our vision. We have been able to significantly advance our portfolio with more than 25 Phase 2 and Phase 3 clinical trials ongoing. As Ugur mentioned, particular focus has been placed on the development of our bispecific immunomodulator candidate pumitamig.

Before I delve into the figures for the 2025 fiscal year, I would like to point out that in my report today, I will always be referring to the BioNTech Group. This includes BioNTech SE along with all its subsidiaries. Since the development of BioNTech SE is largely dependent on the development of the Group, we will refrain from discussing its individual performance separately. Please note, that all figures will be in euros unless otherwise stated.

2025 was a strong year for BioNTech. We exceeded our revenue guidance, which we had raised during the year. We were in line with our already reduced R&D and SG&A expenses guidance for the year.

These results arise from our active portfolio management and strategy where we are focusing our resources on programs that have the biggest potential to elevate patient outcomes and

deliver value for our shareholders. Also important is our tailored, innovative partnership model, which contributed meaningful revenue and cost sharing across multiple programs.

Our total revenues in 2025 were €2.9 billion, a slight increase from the prior year despite the year-over-year decrease in COVID-19 vaccine revenues. The COVID-19 vaccine revenues decline was partially offset by the recognition of €613 million in revenue derived from our collaboration with Bristol Myers Squibb, which I'll refer to as BMS from here on.

R&D expenses were approximately €2.1 billion which is a slight decrease from the prior year despite the acceleration of our late-stage oncology programs. This was enabled by cost savings resulting from our active portfolio management as well as positive effects resulting from cost sharing with BMS for the development of pumitamig. We continue to drive value creation through active portfolio management, shifting toward later stage de-risked programs that have the potential to underpin the next phase of BioNTech's development.

In 2026, our first quarter performance was in line with our expectations and reflects the seasonal demand pattern we expect across quarters for COVID-19 vaccines.

Revenues for the first quarter of 2026 were €118 million. This is compared to €183 million in the same period last year. The decrease was primarily driven by lower demand from our COVID-19 vaccines, as expected.

R&D expenses were €557 million, compared to €526 million in the prior year period. The increase was driven by higher spending on our immuno-oncology and ADC programs - in particular pumitamig and gotistobart - as well as R&D costs from BioNTech China, previously named Biotheus, and CureVac, both of which were acquired in 2025. The R&D spend related to CureVac pertains to inherited ongoing programs that we are currently completing. These increases were partly offset by lower expenses from our COVID-19 vaccine collaboration with Pfizer. On an adjusted basis, R&D expenses were €527 million, excluding one impairment charge for an intangible asset.

SG&A expenses were €151 million, compared to €121 million in the prior year period. The increase was mainly driven by our ongoing commercial build-up and the post-acquisition inclusion of operations from BioNTech China and CureVac.

We ended the first quarter with €16.8 billion in cash, cash equivalents, and security investments. Our strong financial position continues to support sustained investment across our pipeline, including late-stage oncology programs, and our preparations for commercialization.

Turning to the next slide, during our Q1 earnings call, we reaffirmed our previously disclosed full year 2026 financial guidance. All guidance is provided on an adjusted, non-IFRS basis.

We expect total revenues for 2026 in the range of €2.0 to 2.3 billion. As stated at the beginning of the year, we anticipate lower COVID-19 vaccine revenues compared to 2025, driven by declines in both the United States and European markets. The US market continues to be competitive and dynamic. In Europe, we expect lower revenues as we defend our market share and begin managing the transition away from multi-year contracts. In Germany, specifically, we recognize direct sales of our COVID-19 vaccines as revenue. Hence, the anticipated declines in our sales of COVID-19 vaccines in the country will have a direct impact on our topline, whereas revenues outside of Germany only affect our topline as part of the 50% gross profit split with our partner Pfizer.

Revenues from our collaboration with BMS, from the pandemic preparedness contract with the German government, and from our service businesses are expected to remain stable.

On revenue cadence, we anticipate COVID-19 vaccine revenue phasing to be similar to last year, with the last four months of the year driving the majority of the full year revenue figure. The BMS collaboration payment of €613 million is expected to be recognized in the third quarter of 2026.

We expect adjusted R&D expenses in the range of €2.2 to 2.5 billion. Investment will be concentrated on our priority late-stage programs - pumitamig, gotistobart, our ADC pipeline,

and mRNA cancer immunotherapies. We will continue to apply disciplined portfolio prioritization across all development stages.

We expect adjusted SG&A expenses in the range of €700 to 800 million, reflecting our continued commercial build-out in oncology.

During fiscal year 2025 and the first quarter of fiscal year 2026, we conducted three types of capital transactions, two in connection with the acquisition of CureVac and one in connection with our equity-settled employee participation programs. Furthermore, In January 2025, we used the Company's American Depositary Shares, or ADSs, also in the context of the acquisition of Biotheus; this had already been reported at the last Annual General Meeting.

In connection with the acquisition of CureVac, the Authorized Capital 2025 was partially utilized and the Company's share capital was increased twice in quick succession in December 2025, each time excluding shareholders' subscription rights, in exchange for contributions in kind. In total, this resulted in an increase in the Company's share capital of €10,475,287 against contribution of 195,325,137 CureVac shares. The new shares issued from the Authorized Capital 2025 serve as backing for ADSs of the Company, each representing one share, which were offered to the shareholders of CureVac in exchange for their CureVac shares.

In addition, based on the authorization granted under agenda item 10 of the 2024 Annual General Meeting, we used 1,552,300 shares held in treasury, which were converted to ADSs and transferred during the post-offer reorganization in the first quarter of 2026 in exchange for the acquisition of the remaining CureVac shares, excluding shareholders' subscription rights. Together, the ADSs used for the acquisition of CureVac represent about 4.64% of our share capital. The consideration comprised in total 12,027,587 ADSs with a total value of approximately €997.1 million and a cash payment of €4.0 million, resulting in a total value of approximately €1.0 billion.

Using ADSs as acquisition currency allowed us to preserve our cash resources for increasing investment into our late-stage priority programs and strategic capital allocation. The exclusion of subscription rights was necessary to execute the acquisition efficiently and in line with the

applicable regulatory framework, thereby enabling a swift and flexible completion of the acquisition. The shareholders' interests were safeguarded by setting the valuation ratio at an appropriate level, based on a comprehensive assessment of CureVac's intrinsic value and on the price of a BioNTech ADS on NASDAQ. For further information, please refer to the written report of the management board on partial utilization of the Authorized Capital 2025 published on the Company's website.

The second type of capital transaction was related to the CureVac transaction-related award. In connection with the acquisition of CureVac, we granted an award to former management and selected senior leaders of CureVac for their support during the transaction, using 57,211 ADSs held in treasury at a value of approximately €4.5 million, or about 0.02% of our share capital at year-end 2025. The ADSs were used in accordance with the authorization granted under agenda item 10 of the 2024 Annual General Meeting, also excluding shareholders' subscription rights, which allowed us to grant a standard incentive for the transaction.

Finally, the third type of capital transaction in 2025 related to equity-settled employee participation programs. We transferred 822,038 ADSs held in treasury to settle obligations under our equity-settled participation programs ESOP 2018, the second Tranche of the InstaDeep program, the Biotheus founder program and the long-term incentive programs LTI 2020, LTI 2021 and the first Tranche of LTI 2024. This means that we issued these ADSs, in accordance with the authorization granted under agenda item 10 of the 2024 Annual General Meeting, excluding shareholders' subscription rights, to employees participating in the programs. The exclusion of subscription rights was necessary in this context, as the ADSs were issued only to specific individuals eligible under the programs. The issue price per ADS for our option-based programs corresponded to the lowest price on the exercise date, and for our RSU-based programs, to the lowest price on the last trading day before the settlement date. Further details on these programs can be found in our Annual Report 2025 published on the Company's website. In total, these transfers represented approximately 0.32% of our share capital at year-end 2025, corresponding to a value of around €82.7 million.

Apart from these measures and the acquisition of Biotheus, which had already been reported at the last Annual General Meeting, no other capital market authorizations were utilized in the fiscal year 2025. The ADSs used had already been repurchased by the Company before the beginning of the 2025 fiscal year, primarily under our 2023 share repurchase program. This had already been reported to the 2024 Annual General Meeting.

In addition to the post-offer reorganization in connection with the acquisition of CureVac, capital transactions in the first quarter of 2026 were limited to settlements under our employee participation programs. As in 2025, we used ADSs held in treasury, which had already been repurchased before the beginning of the 2025 fiscal year, to settle obligations under the employee participation programs LTI 2021 and ESOP 2018 in accordance with the authorization granted under agenda item 10 of the 2024 Annual General Meeting, excluding shareholders' subscription rights.

In total, 6,621 ADSs were transferred – less than 0.01% of our share capital, with a value of approximately €0.51 million. Apart from these measures, no other capital market authorizations were utilized in the first quarter of 2026.

Before I move on to our approach to capital allocation, I would like to briefly address agenda items 9, 10 and 11. Today, we are seeking your approval on the following matters:

- Under Agenda Item 9, we are proposing to renew the authorization allowing for virtual Annual General Meetings. The Company has consistently had positive experiences with the virtual format, which has established itself as a modern and sustainable meeting format and has since become a widely accepted standard. The virtual format has proven to be an efficient and legally compliant alternative to in-person meetings for the Company. International shareholders in particular benefit from this option, which makes the virtual format especially attractive for the Company as an internationally oriented enterprise whose ADSs are listed in the U.S. on the NASDAQ stock exchange. We therefore propose renewing the authorization to hold virtual Annual General

Meetings but limited to two years to ensure that our shareholders have a say in the format of the Annual General Meeting at regular intervals.

- Under agenda item 10, the Management Board and Supervisory Board propose to revoke the existing Authorized Capital 2025, which was partially utilized and to replace it with a new Authorized Capital 2026 in the amount of 50% of the current share capital. The proposal is intended to provide the Company with the necessary flexibility regarding its financing—both consistently and beyond the year 2026—in a challenging competitive environment, as well as to enable the acquisition of attractive targets in the future in a manner that preserves liquidity ensure that, going forward, authorized capital in the maximum amount and for the maximum period permitted will continue to be available on an ongoing basis, thereby providing the Company with the necessary financial flexibility in a challenging competitive environment. As with the Authorized Capital 2025, the option to exclude subscription rights when issuing new shares will be limited to a total of 10% of the share capital to protect shareholders from dilution of their shareholdings.
- Under agenda item 11, we ask for your approval to enter into a domination and profit and loss transfer agreement - hereinafter also referred to as the “DPLTA”—between BioNTech SE and its wholly-owned subsidiary BioNTech Discovery GmbH.

Through the DPLTA, the subsidiary places its management under the control of the parent company. Thus, BioNTech SE is entitled to issue instructions to the subsidiary’s management. The subsidiary is obligated, in accordance with Section 301 of the German Stock Corporation Act, to transfer its profits to BioNTech SE, while BioNTech SE is obligated to offset any annual net loss of the subsidiary arising during the term of the agreement. The intended conclusion of the DPLTA contributes to integrating the aforementioned subsidiary even more closely into the corporate structure than before. Its primary purpose is to establish a corporate tax and trade tax group, which enables the offsetting of profits arising at the subsidiary level against any losses at the parent company level. In addition, the DPLTA is intended to serve as a basis for organizational integration, which is a prerequisite for a VAT group, and would also have positive

tax implications. We have thoroughly examined how the agreement would affect the company in detail. This includes, among other things, an analysis of the tax, commercial, and corporate law implications, which you can find—along with further details—in the joint report on the DPLTA prepared by the Management Board of BioNTech SE and the management of the subsidiary. This report, along with the other documents subject to disclosure, is available on the Company’s website. The Management Board and the Supervisory Board have jointly concluded that the conclusion of the DPLTA is in the best interests of the Company and therefore ask for your approval today. With this, I would like to conclude my remarks on the agenda items 9 through 11.

Let me now discuss our approach to capital allocation. I would like to highlight 3 key components of our approach to creating long-term shareholder value.

The first component is focused R&D investments to maximize the potential of our pipeline: We actively manage our portfolio, focusing our resources on programs that have the greatest potential to elevate patient outcomes. This means increasing investment into our late-stage priority programs - namely pumitamig, gotistobart, our ADC assets, mRNA cancer immunotherapies, and their respective combinations, while remaining cost-efficient outside of those priority areas.

The second component sees us mobilizing our balance sheet as a statement of confidence in the business. We are initiating a share repurchase program of American Depositary Shares up to an amount of one billion US Dollars over the coming twelve months. Let me walk you through some principles that guided this decision.

- One is opportunistic flexibility: This program gives us the ability to deploy capital during times when our share price may be disconnected from intrinsic company value.
- Another principle is that our pipeline remains the primary driver of value. The buyback is supportive of the share price, but it is not determinative. The real value creation story at BioNTech remains the clinical execution of our oncology pipeline.

- Also - disciplined capital management. This program complements our R&D investment. We retain full optionality to advance our pipeline, execute partnerships and explore corporate development opportunities. Our balance sheet, with €16.8 billion in cash, cash equivalents and security investments, gives us the capacity to do all of this simultaneously.

In short, the share repurchase program reflects confidence in our science, capital management discipline, and a commitment to delivering long-term value for our shareholders.

The third key component of our capital allocation strategy relates to the efficient management of our manufacturing network.

Ugur has already spoken about this and I want to add the operational context. As our company has evolved - moving from pandemic-era manufacturing at scale toward a diversified oncology-focused pipeline - our manufacturing footprint needs to evolve with it. After a thorough assessment, we identified sites where capacity is expected to become significantly underutilized or idle over the next 24 months and the decision was made to exit operations at those sites. These include our sites in Idar-Oberstein, Marburg, and Singapore, as well as the CureVac sites.

This affects approximately 1,800 colleagues - people who have been fundamental to what BioNTech has achieved. I want to be clear that we did not take that decision lightly, and we are committed to handle this process with the full respect and social responsibility that our colleagues deserve, in close dialogue with employee representatives at each site.

In addition, for each site, we are actively exploring divestment options - including a partial or full sale.

The savings expected from these decisions are not an end in themselves - they are intended to fund the next chapter: advancing our growing late-stage oncology pipeline toward commercialization and, ultimately, toward reaching patients. We expect cost savings from these decisions to ramp up over time, potentially reaching approximately €500 million in recurring annual savings upon full implementation by 2029, excluding exit costs, which will be recorded as incurred.

Our commercial and clinical drug supply is not affected by this decision. Future supply for clinical manufacturing of mRNA-based candidates will be covered by BioNTech's broader manufacturing network, for example, in Mainz. Supply for our COVID-19 vaccine will be fully handled by our partner Pfizer from the end of 2026. These plans reflect our commitment to building a company that is both scientifically ambitious and operationally sustainable: a company that can become the multi-product company we are working toward by 2030.

As we look across the three horizons on this slide, we are energized by the progress we have made to date, and the path ahead.

We are making progress towards executing our strategy. We are advancing key programs into pivotal stage, leveraging our partnership with BMS and our fortified balance sheet to fund our pipeline.

From 2026 through 2029, we will drive execution at scale and speed - advancing combination therapy trials, accelerating pivotal trial execution, building tumor indication-specific portfolios, and executing our first oncology launches.

By 2030, our goal is to be a diversified, multi-product global biopharmaceutical company—addressing the high unmet medical needs of cancer patients worldwide.

BioNTech's robust financial position empowers us to pursue that goal. We remain fully committed to translating our science into survival for patients.